Primary sclerosing cholangitis associated colitis: Characterization of clinical, histologic features, and their associations with liver transplantation

Table 1 Clinical characteristics of Primary sclerosing cholangitis-Ulcerative colitis and Primary sclerosing cholangitis-Crohn disease patients (in all available patients, treatment data not mutually exclusive), n (%)

	PSC-UC	UC	P value	PSC-CD	CD	P value	P value (PSC-UC vs PSC-CD)
Male	17 (65)	18 (64)	0.9	5 (83)	2 (22)	0.03a	0.4
Age at the time of biopsy (yr) (mean ± SD)	37 ± 14.61	41 ± 15.55	0.4	38 ± 14.93	32 ± 10.21	0.2	0.8
Age at IBD diagnosis (yr) (mean ± SD)	27± 14.38	30 ± 10.61	0.3	33 ± 14.77	22 ± 10.48	0.09	0.2
Age at PSC diagnosis (yr) (mean ± SD)	32 ± 13.96	NA	NA	31± 12.87	NA	NA	0.8
Interval between PSC and IBD diagnoses (yr) (mean ± SD)	9 ± 10.45	NA	NA	1.4 ± 1.6733	NA	NA	0.1
IBD duration at biopsy (yr) (mean ± SD)	10.8 ± 10.84	9 ± 9.19	0.5	7.00 ± 5.18	9.8 ± 4.06	0.5	0.3
PSC duration (yr) (mean)	6	NA	NA	12.33	NA	NA	0.8
Medical treatment
Ursodiol	9 (35)	0	0.0006a	2 (33)	0	0.1	1
Steroids	8 (31)	19 (68)	0.01a	2 (33)	2 (22)	1	1
ASA	15 (58)	17 (61)	1	2 (33)	6 (67)	0.3	0.4
Anti-TNF	5 (19)	7 (25)	0.7	1 (17)	7 (78)	0.04a	1
Immunomodulators	4 (15)	8 (29)	0.3	2 (33)	3 (33)	1	0.3
Colectomy	10 (38)	19 (68)	0.03a	0	1 (11)	0.9	0.9
OLT	10 (38)	NA	NA	0	NA	NA	0.1
Follow-up duration (yr) (mean ± SD)	8.2 ± 4.61	8.2 ± 5.75	0.9	4.8 ± 2.23	5.9 ± 3.14	0.7	0.1
Development of dysplasia/cancer	4 (15)	5 (18)	0.8	0	0	1	0.9
Resection used in histologic and IHC analysis	6 (23)	9 (32)	0.4	0	3 (33)	0.9	0.9

^aP < 0.05. PSC: Primary sclerosing cholangitis; UC: Ulcerative colitis; CD: Crohn disease; SD: Standard deviation; ASA: 5-aminosalicylic acid; TNF: Tumor necrosis factor; IBD: Inflammatory bowel disease; OLT: Orthotopic liver transplantation; IHC: Immunohistochemistry; NA: Not available.